Skip to main content
. Author manuscript; available in PMC: 2018 Dec 21.
Published in final edited form as: Pharmacogenomics J. 2018 Jun 21;18(5):623–632. doi: 10.1038/s41397-018-0030-8

Figure 3.

Figure 3

Progression-free survival (PFS) and overall survival (OS) in treatment arms in TRIBE study according to G/G or any C PIN1 rs2233678 alleles: arm A receiving FOLFIRI + bevacizumab (irinotecan cohort 1); arm B receiving FOLFOXIRI + bevacizumab (combination cohort).